ABSTRACT
All humans age, but some age faster than others. Variation in biological aging can be measured in midlife, but the implications of this variation are poorly understood. We tested associations between biological aging and indicators of future frailty risk in the Dunedin cohort of 1037 infants born the same year and followed to age 45. Participants’ Pace of Aging was quantified by tracking declining function in 19 biomarkers indexing the cardiovascular, metabolic, renal, hepatic, immune, dental, and pulmonary systems across ages 26, 32, 38, and 45 years, in 2019. Participants with faster Pace of Aging had more cognitive difficulties, signs of advanced brain aging, diminished sensory-motor functions, older appearance, and more pessimistic perceptions of aging. People who are aging more rapidly than same-age peers in midlife may prematurely need supports to sustain independence that are usually reserved for older adults. Chronological age does not adequately identify need for such supports.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the National Institute on Aging (NIA) grants R01AG032282 and R01AG049789, and the UK Medical Research Council grant MR/P005918/1. Additional support was provided by the Jacobs Foundation, NIA P30 AG028716, and NIA P30 AG034424. The Dunedin Multidisciplinary Health and Development Research Unit was supported by the New Zealand Health Research Council (Project Grants 15-265 and 16-604) and the New Zealand Ministry of Business, Innovation, and Employment (MBIE). MLE is supported by the National Science Foundation Graduate Research Fellowship (NSF DGE-1644868) and NIA F99 AG068432-01.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from cohort participants. Ethical approval for the study protocols was given by the campus Institutional Review Board of Duke University and the Health and Disability Ethics Committees of the New Zealand government.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The Dunedin Study datasets reported in the current article are not publicly available due to lack of informed consent and ethical approval, but are available on request by qualified scientists. Requests require a concept paper describing the purpose of data access, ethical approval at the applicant's university and provision for secure data access (https://moffittcaspi.trinity.duke.edu/research-topics/dunedin). We offer secure access on the Duke, Otago and King's College campuses.
